此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项针对超重或肥胖人群的研究,比较两种不同配方的Survodutide在体内的吸收情况

2026年11月12日 更新者:Boehringer Ingelheim

两种Survodutide (BI 456906)制剂经皮下多次给药后的生物等效性(一项开放标签、随机、多次给药、交叉试验)

The primary objective of this trial is to assess bioequivalence of two formulations of survodutide (formulation A and formulation B6) after multiple-dose treatment in male and female trial participants living with overweight or obesity.

研究概览

研究类型

介入性

注册 (实际的)

80

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Nottingham、英国、NG11 6JS
        • Quotient Sciences

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Healthy male or female trial participant according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), and clinical laboratory tests

  2. Age of 18 to 65 years (inclusive)

  3. Body Mass Index (BMI) of 27.0 to 39.9 Kg/ m^2 (inclusive)

  4. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial

  5. For women of child-bearing potential (WOCBP) trial participants: Woman of childbearing potential (WOCBP) trial participants who meet any of the following criteria for a highly effective contraception from at least 28 days before the first administration of trial medication until 28 days after trial completion:

    • Use of combined (estrogen and progestogen containing) hormonal contraception that prevents ovulation (oral, intravaginal or transdermal). In case of oral contraception, a barrier method should be used in addition or advised to change to non-oral contraceptives at least 7 days prior to first dose of investigational medicine product (IMP)
    • Use of progestogen-only hormonal contraception that inhibits ovulation (only injectables or implants). In case of oral contraception, a barrier method should be used in addition or advised to change to non-oral contraceptives at least 7 days prior to first dose of IMP
    • Use of intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)
    • Complete abstinence (refraining from heterosexual intercourse during the entire period of risk associated with the study treatment) is considered a highly effective method of contraception only if it is in line with the preferred and usual lifestyle of the trial participant. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of exposure to trial IMP, spermicides only, lactational amenorrhoea method (LAM) and withdrawal are not acceptable methods of contraception
    • Bilateral tubal ligation/occlusion is considered a highly effective method of contraception, provided that the procedure has not been reversed or failed.
    • Surgically sterilised (including hysterectomy, bilateral salpingectomy and bilateral oophorectomy)
    • Postmenopausal, defined as no menses for 1 year without an alternative medical cause

Exclusion Criteria:

  1. Any finding in the medical examination (including BP, PR) or ECG) deviating from normal and assessed as clinically relevant by the investigator
  2. Repeated measurement of systolic Blood pressure (BP) outside the range of 90 to 150 mmHg, diastolic BP outside the range of 50 to 100 mmHg, or PR outside the range of 50 to 100 bpm
  3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance.
  4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator.
  5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders.
  6. Diseases of the Central nervous system (CNS) (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  7. History of relevant orthostatic hypotension, fainting spells, or blackouts
  8. Relevant chronic or acute infections within the 4 weeks prior to screening Further exclusion criteria apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:制剂A,然后制剂B6

Formulation A of survodutide

Formulation B6 of survodutide

实验性的:制剂B6,然后制剂A

Formulation A of survodutide

Formulation B6 of survodutide

研究衡量的是什么?

主要结果指标

结果测量
大体时间
稳态下,survodutide在血浆中的浓度-时间曲线下面积,在均匀给药间隔tau期间(AUC tau,ss)
大体时间:最长可达239天。
最长可达239天。
稳态下均匀给药间隔tau(τ)内血浆中survodutide的最大测量浓度(Cmax,ss)
大体时间:最多239天。
最多239天。

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年3月11日

初级完成 (估计的)

2027年4月9日

研究完成 (估计的)

2027年4月9日

研究注册日期

首次提交

2026年2月6日

首先提交符合 QC 标准的

2026年2月6日

首次发布 (实际的)

2026年2月12日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 1404-0066
  • U1111-1323-8960 (注册表标识符:WHO - International Clinical Trials Registry Platform (ICTRP))

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).

For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅